Trial Profile
A Randomized, Double-Blind, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Effect on Pharmacodynamic Biomarkers of an Intravenous Infusion of R1671 in Patients With Mild, Intermittent Asymptomatic Asthma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2014
Price :
$35
*
At a glance
- Drugs R 1671 (Primary)
- Indications Asthma
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Roche
- 17 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2009 Actual patient number (43) added as reported by ClinicalTrials.gov.
- 15 May 2009 Planned end date changed from 1 Aug 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov record.